In vivo synergism of roxithromycin (RU 965) and interferon against Toxoplasma gondii
Open Access
- 1 February 1987
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 31 (2) , 346-348
- https://doi.org/10.1128/aac.31.2.346
Abstract
We investigated the activity of roxithromycin (RU 965) and gamma interferon alone and in combination in a murine model of toxoplasmic encephalitis. Roxithromycin at a dosage of 35 or 50 mg per mouse per day decreased mortality. Gamma interferon alone significantly prolonged time to death. When combined, the two agents were remarkably synergistic.This publication has 8 references indexed in Scilit:
- In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii.The Journal of Immunology, 1985
- Effect of Murine Interferon Gamma on Murine ToxoplasmosisThe Journal of Infectious Diseases, 1984
- Adverse Reactions to Trimethoprim-Sulfamethoxazole in Patients with the Acquired Immunodeficiency SyndromeAnnals of Internal Medicine, 1984
- Assessment of therapy for Pneumocystis carinii pneumoniaThe American Journal of Medicine, 1984
- Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.The Journal of Experimental Medicine, 1983
- Interferon: Protection of Cells Infected with an Intracellular Protozoan ( Toxoplasma gondii )Science, 1968